Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search

Pages

13974 items
11:27 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Other News

Roche culls pipeline, cuts include in-licensed, acquired programs

Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...
11:26 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Other News

WideTrial seeks to increase expanded access programs by helping companies recover costs

FDA has authorized WideTrial Inc. (San Francisco, Calif.) to charge payment for an expanded access program for critical limb ischemia (CLI) candidate PLX-PAD from Pluristem Therapeutics Inc. (NASDAQ:PSTI; Tel Aviv:PSTI) under a cost recovery program....
11:11 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Other News

Changsheng fined $1.3B after vaccine scandal

China's National Medical Products Administration (NMPA) fined Changsheng Bio-Technology Co. Ltd. (SZSE:002680) RMB7.2 billion ($1 billion) for eight counts of manufacturing violations, falsification of records and destruction of evidence associated with the illegal production of...
10:46 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Other News

Trump signs law intended to deter 'pay-for-delay' deals for biosimilars

President Donald Trump signed the Patient Right to Know Drug Prices Act (S.2554) into law on Oct. 10, which includes a provision to make it more difficult for branded drugmakers to strike “pay-for-delay” deals with...
11:42 AM, Oct 12, 2018  |  BC Week In Review | Company News  |  Other News

Japan issues draft guidance for gene editing in human embryos

Science Council of Japan, Tokyo, Japan  Business: Other  Japan issued draft guidelines on Sept. 28 that would allow gene editing in human embryos, with a restriction on manipulating human embryos for reproduction, according to a Nature news...
10:59 AM, Oct 12, 2018  |  BC Week In Review | Company News  |  Other News

Arbutus falls on HBV program updates

Arbutus Biopharma Corp. (NASDAQ:ABUS) lost $3.09 (34%) to $6 on Oct. 9 after announcing updates for two of its HBV programs. The move translated to a loss of over $170 million in the company's market...
3:56 PM, Oct 11, 2018  |  BC Week In Review | Company News  |  Other News

Novartis launches Biome health tech initiative

Novartis AG (NYSE:NVS; SIX:NOVN) launched Novartis Biome to help the pharma identify and develop digital health technology. Novartis Biome includes a digital innovation lab and several ways for innovators and start-ups to work alongside Novartis...
1:53 PM, Oct 05, 2018  |  BC Week In Review | Company News  |  Other News

GenScript denies data fraud claims, engages legal counsel

GenScript Biotech Corp. (HKSE:1548) recovered about HK$2.5 billion ($319.3 million) in market cap Sept. 28 after denying all allegations published in a report by short seller Flaming Research. The biotech lost about HK$8 billion ($1 billion)...
1:41 PM, Oct 05, 2018  |  BC Week In Review | Company News  |  Other News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...
1:39 PM, Oct 05, 2018  |  BC Week In Review | Company News  |  Other News

U.K. judge upholds preferred prescribing of Avastin off label for wet AMD

A U.K. judge upheld in September a policy of prescribing Avastin bevacizumab as the preferred treatment option for wet age-related macular degeneration (AMD) over Eylea aflibercept and Lucentis ranibizumab. Avastin does not have marketing authorization...

Pages